Ana María Vesga's appointment as Colombia's new Minister of Health for De la Espriella’s Government is worth reading closely. Not because a single minister determines the fate of a health system, but because the choice offers an early clue to how the incoming government understands the pressures facing the system, and whether it leans toward stabilization or structural reinvention.
A different profile for the Ministry
Vesga brings a background spanning health insurance, industry and health economics to a ministry the last government tried to steer the other way. Seen simply as a matter of profile, the appointment places the system in the hands of someone who, in recent years, defended the insurance model the outgoing administration sought to dismantle, and whose training sits at the intersection of law and health economics. She joins the Ministry from the Colombian Association of Comprehensive Healthcare Companies (ACEMI), the trade association representing the Health Promoting Entities (Entidades Promotoras de Salud, EPS), which manage health insurance under Colombia's contributory system. Before that she led the pharmaceutical chamber and then the health division of the National Business Association of Colombia (Asociación Nacional de Empresarios de Colombia, ANDI), after some fifteen years in the hydrocarbons sector. How far that background shapes her tenure could decide where the health system goes next.
A sector under strain
The early signs favor stabilization. Under Gustavo Petro, two reform attempts failed in Congress, and the government pressed ahead by administrative means, intervening several EPS and concentrating much of the country's coverage in Nueva EPS, its largest state-controlled insurer. On Superintendency of Health data reported in the local press, the aggregate equity deficit of the EPS, excluding Nueva EPS, widened from around 429 billion pesos in early 2022 to roughly 18 trillion in negative territory by early 2026. Vesga's early language as minister designate, centered on liquidity, on correcting lags in the capitation payment, and on settling the accumulated debts of the maximum budget mechanism, points to a first year focused on operational stabilization rather than a new model.
Events have since overtaken that agenda. On August 10th a major earthquake struck western Colombia, damaging health infrastructure across several departments. It has strained continuity of care where facilities were lost, raised the risk of disease outbreaks in overcrowded shelters, and pulled scarce resources toward response and reconstruction. Vesga has said the disaster forced the government to reorder its priorities. For a ministry already stretched by the system's financial pressures, it adds an operational burden.
Stabilization before reform
Even amid the emergency, the underlying direction of policy still favors continuity and stabilization over structural reinvention. President Abelardo de la Espriella has said he does not intend to liquidate the EPS or abandon the insurance model, and his stated program leans on familiar instruments: tighter auditing of the capitation payment, restored price controls on medicines and technologies, and firmer administrative oversight. The most contested inheritance, an oversized Nueva EPS, is expected to be managed and restructured rather than dismantled. For companies and investors braced for structural upheaval, a more predictable policy environment would be welcome, though the reconstruction now competes for the same scarce resources.
The sequencing is where there is room to take a different approach. Vesga has said she wants to stabilize first and convene the sector before promoting any new reform, a departure from the confrontational rhythm of recent years. If that holds, it could reopen a mode of engagement that had largely closed. A minister who comes directly from the EPS trade association brings deep knowledge of the system and long relationships across the sector. At the same time, her appointment is likely to raise questions among some stakeholders about independence and governance. Managing those perceptions, and building trust across government, providers, patients and industry, may matter as much as her technical decisions.
Implications for innovation and access
Innovation and market access follow a similar pattern. Based on its stated priorities, the incoming administration does not obviously favor premium-priced therapies. Even so, Vesga has indicated that patients with the most complex needs, those with cancer, chronic conditions, transplants and rare diseases, will remain a priority. For manufacturers, much will depend on restoring the fundamentals: clearing payment backlogs, improving reimbursement predictability and rebuilding confidence in how care is financed.
Rare diseases offer a useful test of whether that promise to patients translates into practice. Colombia has been, on paper, one of the region's more progressive jurisdictions on this front, recognizing more than two thousand orphan conditions, building a national plan, moving toward centralized procurement, and helping advance a rare disease resolution at the World Health Organization. The persistent gap has been in implementation: late diagnosis, uneven financing through capitation and maximum budgets, and disruptions in treatment continuity that the earthquake has now sharpened. Vesga's background suggests a strong understanding of these challenges. Whether enough fiscal and operational capacity exists to protect these patients' access matters more now than before.
It is tempting to read a change of government as a turning point. The more measured expectation is that health systems evolve gradually, and that a minister's first year shapes priorities, governance and relationships more than it reshapes the system itself. Vesga now has to stabilize an already strained system while managing the response and recovery, which makes fiscal space, continuity of care and implementation more pressing than reform debates. For healthcare companies, there may be a constructive role to play in supporting continuity of care, system resilience and patient access. Even if systemic transformation takes time, sustained dialogue can still deliver meaningful progress.
FAQ
What does the new health minister mean for market access in Colombia?
The appointment signals stabilization rather than structural reinvention. Ana Maria Vesga arrives from ACEMI, the trade association representing the EPS insurers, and her stated first-year priorities are liquidity, capitation adjustment and settlement of accumulated debts. For companies assessing Colombia market access healthcare conditions, this points toward gradual restoration of payment fundamentals rather than a redesigned reimbursement architecture.
Will Colombia's new government dismantle the EPS insurance model?
The published government program states it does not seek to dismantle insurance or eliminate the EPS, relying instead on tighter controls: quarterly review of capitation execution, restored maximum budget policy, strengthened price controls and caps on administrative costs. However, the Minister has said liquidations will proceed for intervened insurers that cannot be saved. The model is preserved; individual entities are not guaranteed.
How can Speyside help companies navigate Colombia's health sector transition?
Speyside Group supports investors, multinational corporations and corporate affairs teams assessing market access and regulatory risk across emerging markets. In Colombia, this includes mapping the stakeholder landscape across the Ministry, the Superintendency of Health, ADRES and the insurer and provider associations, monitoring implementation of capitation and maximum budget policy as rules are written, and building the evidence-led engagement positions that allow organizations to participate credibly in sector consultation. Where the operating environment is being rebuilt rather than redesigned, early and well-founded engagement is what separates organizations that shape implementation from those that absorb it.
Conclusion
The direction of travel in Colombia is toward repair rather than reinvention, and that shift changes what competence looks like. For the better part of four years, the decisive question for companies operating in the health sector was whether the model itself would survive; it is now whether the institutions inside that model can be made to function while a damaged system absorbs a reconstruction it did not plan for. That is a quieter test, and a harder one. Organizations that succeed in this environment will be those that treat stabilization as a participatory process rather than a spectator event: that track implementation at the level of capitation methodology and payment settlement rather than headline policy, that hold positions grounded in evidence when consultation channels reopen, and that build relationships across a fragmented stakeholder landscape before decisions narrow.
